TrialInvestigational new drugs2016

An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.

Andrea Necchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.